Abstract:Rationale: TGF-β/Smad signaling is the central mediator for renal fibrosis, however, its functional role in acute kidney injury (AKI) is not fully understood. We previously showed Smad2 protects against renal fibrosis by limiting Smad3 signaling, but details on its role in acute phase are unclear. Recent evidence showed that TGF-β/Smad3 may be involved in the pathogenesis of AKI, so we hypothesized that Smad2 may play certain roles in AKI due to its potential effect on programmed cell death. Methods: We established a cisplatin-induced AKI mouse model with TGF-β type II receptor or Smad2 specifically deleted from renal tubular epithelial cells (TECs). We also created stable in vitro models with either Smad2 knockdown or overexpression in human HK2 cells. Importantly, we evaluated whether Smad2 could serve as a therapeutic target in both cisplatin- and ischemic/reperfusion (I/R)-induced AKI mouse models by silencing Smad2 in vivo. Results: Results show that disruption of TGF-β type II receptor suppressed Smad2/3 activation and attenuated renal injury in cisplatin nephropathy. Furthermore, we found that conditional knockout of downstream Smad2 in TECs protected against loss of renal function, and alleviated p53-mediated cell apoptosis, RIPK-mediated necroptosis and p65 NF-κB-driven renal inflammation in cisplatin nephropathy. This was further confirmed in cisplatin-treated Smad2 knockdown and overexpression HK2 cells. Additionally, lentivirus-mediated Smad2 knockdown protected against renal injury and inflammation while restoring renal function in established nephrotoxic and ischemic AKI models. Conclusions: These findings show that unlike its protective role in renal fibrosis, Smad2 promoted AKI by inducing programmed cell death and inflammation. This may offer a novel therapeutic target for acute kidney injury.

Smad2 Protects Against TGF-β/Smad3-Mediated Renal Fibrosis

Smad7 Inhibits Fibrotic Effect of TGF- on Renal Tubular Epithelial Cells by Blocking Smad2 Activation

Smad3 mediates ANG II-induced hypertensive kidney disease in mice.

Smad3 Signaling Activates Bone Marrow-Derived Fibroblasts in Renal Fibrosis

Mir-192 Mediates TGF-beta/Smad3-driven Renal Fibrosis.

The Smad3/Smad4/CDK9 Complex Promotes Renal Fibrosis in Mice with Unilateral Ureteral Obstruction.

Smad3 Mediates Cardiac Inflammation and Fibrosis in Angiotensin II–Induced Hypertensive Cardiac Remodeling

Mice overexpressing latent TGF-β1 are protected against renal fibrosis in obstructive kidney disease

Disruption of Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro.

TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29.

Mice Overexpressing Latent Tgf-Beta 1 Are Protected Against Renal Fibrosis In Obstructive Kidney Disease

Disruption of Smad7 Promotes ANG II-Mediated Renal Inflammation and Fibrosis Via Sp1-TGF-β/Smad3-NF.κB-Dependent Mechanisms in Mice

Regulation of Renal Fibrosis by Smad3 Thr388 Phosphorylation

SIRT2 Alleviated Renal Fibrosis by Deacetylating SMAD2 and SMAD3 in Renal Tubular Epithelial Cells.

Smad7 Protects Against Acute Kidney Injury by Rescuing Tubular Epithelial Cells from the G1 Cell Cycle Arrest.

Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis

FSP1-specific SMAD2 knockout in renal tubular, endothelial, and interstitial cells reduces fibrosis and epithelial-to-mesenchymal transition in murine STZ-induced diabetic nephropathy

Conditional knockout of TGF-βRII /Smad2 signals protects against acute renal injury by alleviating cell necroptosis, apoptosis and inflammation

Essential Role Of Smad3 In Angiotensin Ii-Induced Vascular Fibrosis

UP-REGULATION OF SMAD2/3 CONTRIBUTES TO RENAL FIBROSIS AND CELL APOPTOSIS IN OBSTRUCTIVE NEPHROPATHY OF RATS

Diverse Roles of TGF‐β Receptor II in Renal Fibrosis and Inflammation in Vivo and in Vitro